Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study
Top Cited Papers
Open Access
- 11 March 2010
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 115 (10), 1886-1892
- https://doi.org/10.1182/blood-2009-09-243154
Abstract
Despite recent advances in understanding the pathophysiologic mechanisms behind the thalassemia intermedia (TI) phenotype, data on the effects of treatment are deficient. To provide such data, we evaluated 584 TI patients for the associations between patient and disease characteristics, treatment received, and the rate of complications. The most common disease-related complications were osteoporosis, extramedullary hematopoeisis (EMH), hypogonadism, and cholelithiasis, followed by thrombosis, pulmonary hypertension (PHT), abnormal liver function, and leg ulcers. Hypothyroidism, heart failure, and diabetes mellitus were less frequently observed. On multivariate analysis, older age and splenectomy were independently associated with an increased risk of most disease-related complications. Transfusion therapy was protective for thrombosis, EMH, PHT, heart failure, cholelithiasis, and leg ulcers. However, transfusion therapy was associated with an increased risk of endocrinopathy. Iron chelation therapy was in turn protective for endocrinopathy and PHT. Hydroxyurea treatment was associated with an increased risk of hypogonadism yet was protective for EMH, PHT, leg ulcers, hypothyroidism, and osteoporosis. Attention should be paid to the impact of age on complications in TI, and the beneficial role of splenectomy deserves revisiting. This study provides evidence that calls for prospective evaluation of the roles of transfusion, iron chelation, and hydroxyurea therapy in TI patients.Keywords
This publication has 36 references indexed in Scilit:
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2009
- Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermediaHaematologica, 2008
- Relation Between Iron-Overload Indices, Cardiac Echo-Doppler, and Biochemical Markers in Thalassemia IntermediaThe American Journal of Cardiology, 2008
- Liver iron concentrations and urinary hepcidin in -thalassemiaHaematologica, 2007
- Increased prevalence of iron‐overload associated endocrinopathy in thalassaemia versus sickle‐cell diseaseBritish Journal of Haematology, 2006
- Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and IranThrombosis and Haemostasis, 2006
- Coagulation and Splenectomy: An OverviewAnnals of the New York Academy of Sciences, 2005
- Hydroxyurea can eliminate transfusion requirements in children with severe β-thalassemiaBlood, 2003
- PULMONARY THROMBOEMBOLISM IN β-THALASSEMIA INTERMEDIA: ARE WE AWARE OF THIS COMPLICATION?Hemoglobin, 2002
- Relationship between Genotype and Phenotype: Thalassemia IntermediaaAnnals of the New York Academy of Sciences, 1998